Document resource
Autoimmune glial fibrillary acidic protein (GFAP) astrocytopathy is a rare Central Nervous System (CNS) inflammatory disorder, first defined in 2016 and identified by GFAP-IgG in cerebrospinal fluid (CSF). Its rarity makes large-scale studies nearly impossible, so each well-designed case series is valuable. Within this context, Handa et al’s study is noteworthy for its design1; they included a well-matched disease control group and conducted thorough CSF analyses (Epstein-Barr virus (EBV) DNA PCR and serology), strengthening the validity of their findings.